Advanced search

Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.

Author
Organization

Citation

Please use this url to cite or link to this publication:

Chicago
Van Den Bosch, Filip, Dominique Baeten, Elli Kruithof, Filip De Keyser, Herman Mielants, and Eric Veys. 2001. “Treatment of Active Spondyloarthropathy with Infliximab, the Chimeric Monoclonal Antibody to Tumour Necrosis Factor Alpha.” Annals of the Rheumatic Diseases 60: 33.
APA
Van Den Bosch, F., Baeten, D., Kruithof, E., De Keyser, F., Mielants, H., & Veys, E. (2001). Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha. ANNALS OF THE RHEUMATIC DISEASES, 60, 33.
Vancouver
1.
Van Den Bosch F, Baeten D, Kruithof E, De Keyser F, Mielants H, Veys E. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha. ANNALS OF THE RHEUMATIC DISEASES. 2001;60:33.
MLA
Van Den Bosch, Filip, Dominique Baeten, Elli Kruithof, et al. “Treatment of Active Spondyloarthropathy with Infliximab, the Chimeric Monoclonal Antibody to Tumour Necrosis Factor Alpha.” ANNALS OF THE RHEUMATIC DISEASES 60 (2001): 33. Print.
@article{169945,
  author       = {Van Den Bosch, Filip and Baeten, Dominique and Kruithof, Elli and De Keyser, Filip and Mielants, Herman and Veys, Eric},
  issn         = {0003-4967},
  journal      = {ANNALS OF THE RHEUMATIC DISEASES},
  language     = {eng},
  pages        = {III33-III36 Suppl. 3},
  title        = {Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.},
  volume       = {60},
  year         = {2001},
}

Web of Science
Times cited: